Dive Into Other Topics

Mar 02, 2025

On September 29, 2023, FDA approved EXXUA, the ER gepirone hydrochloride tablets by Fabre-Kramer, for major depressive disorder treatment.

Feb 12, 2025

Donanemab is a promising new Alzheimer’s disease treatment. Donanemab has the potential to rule the Alzheimer’s disease market.

Feb 12, 2025

Despite facing significant setbacks, companies such as Eli Lilly, BioVie, and others are developing effective Alzheimer's disease treatments.

Feb 12, 2025

Alzheimer’s disease has become one of the most pressing global health challenges, with its prevalence rising dramatically over the past few years. As the aging population grows, so does the burden of this neurodegenerative disorder, placing immense strain on healthcare systems worldwide. The Alzheimer's drug market...

Nov 29, 2024

The evolving landscape of NSCLC treatment presents significant market opportunities for pharmaceutical companies to secure their place.

Aug 13, 2024

To challenge Roche’s dominance in HER2-positive breast cancer treatment market, several other companies are also actively working in domain.

Jul 25, 2024

BMS has established a comprehensive treatment strategy, with CELMODs replacing REVLIMID in earlier lines of multiple myeloma treatment.

May 20, 2024

Currently, a variety of candidate drugs for the treatment of atopic dermatitis are being tested in various clinical trials, with some showing positive results. Any drug approved with increased safety and efficacy is expected to cause significant changes in the overall atopic dermatitis market.

May 17, 2024

One of the most notable advancements in the anti-TIGIT landscape was the collaboration between GlaxoSmithKline and iTeos Therapeutics, around the time of peak TIGIT mania in 2021, culminating in a USD 625 million deal for the anti-TIGIT monoclonal antibody Belrestotug (EOS-448)

Nov 20, 2023

Within a three-day period, Phathom Pharmaceuticals achieves dual FDA approvals for Voquezna, its groundbreaking heartburn medication.